A simple blood test could reveal what a brain biopsy shows
At the Indian Institute of Science in Bengaluru, researchers have found that the blood of brain tumor patients carries quiet signals about their fate — specific immune markers that may reveal, without a single surgical incision, how aggressively a glioma will advance and how long a patient might survive. In a disease where conventional therapies have long fallen short and even immunotherapy has struggled, this discovery opens a gentler and potentially more precise way to read the illness. The work is still early, a proof of concept awaiting larger validation, but it points toward a future where a blood draw might guide life-and-death treatment decisions for some of medicine's most vulnerable patients.
- Late-stage glioma patients face one of oncology's most unforgiving prognoses, with tumors that resist chemotherapy and confound even the newest immunotherapies.
- The core tension lies in a diagnostic gap: understanding a tumor's immune profile currently requires invasive brain biopsies, delaying treatment decisions and adding risk to already fragile patients.
- IISc researchers discovered that M2 monocytes — immune cells that actively suppress the body's defenses — appear in far greater numbers in the blood of grade four glioma patients, helping explain why the immune system fails to mount a fight.
- Two surface proteins, CD86 and CD63, were found to mirror tumor tissue levels when measured in blood alone, suggesting a non-invasive window into the tumor's behavior.
- The research team is now planning larger-scale studies to validate these markers across broader patient cohorts before any clinical adoption can begin.
A research team at the Indian Institute of Science in Bengaluru has identified specific immune markers in blood that may predict disease progression and survival in patients with advanced brain tumors. By studying blood and tumor samples from patients with grade three and grade four gliomas — the most aggressive and treatment-resistant forms of brain cancer — the scientists found patterns that could one day replace the need for invasive biopsies.
Gliomas originate within the brain itself and carry a grim prognosis at their later stages. Conventional chemotherapy offers little, and immunotherapy, though promising in other cancers, has struggled to gain traction against gliomas. The IISc team, working in partnership with the Mazumdar Shaw Centre for Translational Research, sought to understand the immune landscape of these tumors — and whether that landscape could be read from the blood rather than the brain.
The work demanded careful handling: blood samples are living tissue, and the cells the researchers needed to study are easily destroyed. What emerged from their meticulous analysis was a clear pattern. A type of immune cell called M2 monocytes appeared in significantly higher concentrations in grade four patients — cells known to suppress immune responses, which may help explain why the body cannot fight back effectively against the most advanced tumors.
More striking still was the behavior of two surface proteins — CD86 and CD63 — whose levels in blood closely matched their levels in tumor tissue. In other cancers, elevated levels of these proteins have been associated with poor survival. The implication is significant: a clinician could assess a patient's tumor immune profile through a simple blood test rather than a surgical procedure, enabling faster and better-informed treatment decisions.
Senior author Siddharth Jhunjhunwala was measured in his optimism. The study was a pilot, limited in scale, and the markers must be validated across far larger patient groups before they can enter clinical practice. The team plans to expand their cohort, focus on these two proteins specifically, and track survival outcomes over time. The discovery is a promising beginning — but the distance between laboratory finding and hospital bedside remains real and deliberate.
A team at the Indian Institute of Science in Bengaluru has found a way to read a patient's blood like a map of their brain tumor's future. By comparing immune cells in blood samples against tumor tissue from patients with advanced gliomas—the most aggressive forms of brain cancer—the researchers identified specific markers that could predict how quickly the disease will progress and how long a patient might survive.
Gliomas are tumors that originate in the brain itself, and the late-stage versions—grade three and grade four—carry a grim prognosis. These tumors resist conventional chemotherapy. In recent years, doctors have turned to immunotherapy, attempting to wake the immune system and direct it against cancer cells. But even these newer approaches have struggled against gliomas, leaving clinicians with limited tools and patients with few good options. The research team, drawn from IISc's Centre for BioSystems Science and Engineering and partnered with the Mazumdar Shaw Centre for Translational Research, set out to understand why.
They collected blood and tumor samples from patients with grade three and grade four gliomas, then examined the immune cells present in each. The work required meticulous care—blood samples are living tissue, and any mishandling destroys the very cells the researchers needed to study. The team split the work between two labs: one institute handled the delicate preservation and preparation of the samples, while IISc performed the detailed analysis and staining. What emerged from this careful work was a pattern. A particular type of immune cell called M2 monocytes appeared in much higher numbers in the blood of patients with grade four tumors. Previous research has shown that high numbers of M2 monocytes actually suppress immune responses, which helps explain why the body struggles to fight these advanced cancers.
But the most striking finding involved two surface proteins on immune cells: CD86 and CD63. The researchers discovered that the levels of these proteins in blood samples closely mirrored the levels in tumor tissue itself. In other cancers, high levels of these proteins have been linked to poor survival outcomes. What matters here is the implication: a clinician would not need to biopsy a patient's brain tumor to assess these markers. A simple blood test could reveal the same information.
Siddharth Jhunjhunwala, the senior author and an assistant professor at BSSE, explained the significance. Blood-based biomarkers could allow doctors to identify which patients might not respond well to particular treatments and to choose a more effective strategy from the start. Rather than subjecting patients to invasive procedures or waiting months to see whether a chosen therapy is working, clinicians could make more informed decisions quickly, based on what the blood reveals about the tumor's immune profile.
Yet Jhunjhunwala was careful not to overstate what the research shows. The study was a pilot—a proof of concept with a limited number of patients. Before these markers move from the laboratory into clinical practice, the team needs to test them on a much larger scale. They plan to expand their patient cohort, focus specifically on these two markers in grade three and four glioma patients, and track survival outcomes over time. Only then will they have the evidence needed to convince hospitals and regulatory bodies that blood testing can reliably predict which patients will do well and which will not. The research has identified a promising path forward, but the journey from discovery to bedside remains incomplete.
Citações Notáveis
Blood-based testing could help clinicians better understand disease progression and choose a more effective treatment regimen— Siddharth Jhunjhunwala, Assistant Professor at IISc and senior author
You do not need to look at these markers only in the tumors; you might be able to look at these just from the blood, and the clinician can make an assessment— Siddharth Jhunjhunwala
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that these markers appear in the blood rather than just in the tumor itself?
Because getting to a brain tumor means surgery or biopsy—real risk, real cost. A blood test is simple, repeatable, and you can do it often. If the markers in blood tell you what's happening in the tumor, you've just removed a major barrier to understanding your patient's disease.
So this is about speed and safety, not just new information?
Exactly. You can make treatment decisions faster. You can monitor whether a therapy is working without waiting months or putting the patient through another procedure. That changes how aggressively you can adapt the treatment plan.
The researchers found M2 monocytes in higher numbers in grade four tumors. What does that actually mean for a patient?
It means their immune system is being suppressed by their own tumor. The cancer has essentially recruited immune cells that help it hide. That's why immunotherapy alone hasn't worked well for these patients—you're trying to activate an immune system that's already been compromised.
Can they fix that? Can they reduce the M2 monocytes?
That's the next question. The researchers suggest future therapies might target those cells directly or change how they behave. But that's still theoretical. Right now they've identified the problem; solving it is the work ahead.
How confident are they that this will actually work in the clinic?
Cautious. They're explicit about it—they need larger studies, longer follow-up, validation on many more patients. What they have is a strong signal, not yet proof. The path from here to a hospital blood test is still years away.